ARS Pharmaceuticals Under Investigation Following Failed Formulary Goal

The sharp market decline stems from a widening gap between management’s public projections and the company's recent commercial performance. Throughout 2025, CEO Richard Lowenthal repeatedly assured shareholders that Neffy would gain coverage from major providers, including CVS Caremark, Anthem, and Aetna, in time for the peak summer prescribing season. During the Q4 2024 earnings call, Lowenthal expressed confidence that the company would achieve over 80% coverage by mid-2025. Chief Commercial Officer Eric Karas echoed this optimism, setting a goal for 60% commercial coverage by the end of the first quarter of 2026.

Despite these assurances, the July 2026 payer cycle yielded zero new coverage decisions. This failure arrived after management had already dismissed previous growth slowdowns in late 2025 as merely one-time events. The law firm Levi & Korsinsky has now launched an inquiry into whether the company’s officers and directors issued materially misleading statements regarding the timeline for Neffy’s market penetration. Investors who purchased SPRY shares and suffered financial losses are being urged to review their legal options as the firm examines potential violations of securities law.